Pfizer announced Monday it had agreed to acquire Array Biopharma for $ 10.64 billion, which would give it access to its anti-cancer drugs.
The cash deal for $ 48 per share of Array represents a premium of about 62% over the closing price of the stock on Friday.
The boards of directors of both companies have approved the merger.
It's breaking news. Please check again for updates.